|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
|
WO1993000807A1
(en)
|
1991-07-03 |
1993-01-21 |
Cryolife, Inc. |
Method for stabilization of biomaterials
|
|
EP0638091B1
(en)
|
1992-04-30 |
2005-12-07 |
Probitas Pharma Inc. |
Improved solubilization and stabilization of factor viii complex
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Ｖｅｇｆ結合性ポリペプチド
|
|
EP0797999A3
(en)
|
1996-03-26 |
2002-09-25 |
Eli Lilly And Company |
Formulations of obesity protein
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
DE69900746T2
(de)
|
1998-01-30 |
2002-08-14 |
Scios Inc., Mountain View |
Gesteuerte verabreichung von peptiden oder proteinen
|
|
US7001892B1
(en)
|
1999-06-11 |
2006-02-21 |
Purdue Research Foundation |
Pharmaceutical materials and methods for their preparation and use
|
|
EP1067182A3
(en)
|
1999-07-08 |
2001-11-21 |
Helix Research Institute |
Secretory protein or membrane protein
|
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
|
EP1257572A2
(en)
|
2000-02-07 |
2002-11-20 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
|
US6629949B1
(en)
|
2000-05-08 |
2003-10-07 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
|
US6659982B2
(en)
|
2000-05-08 |
2003-12-09 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
|
MXPA03002046A
(es)
|
2000-09-08 |
2003-07-24 |
Massachusetts Inst Technology |
Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
|
|
WO2002030463A2
(en)
|
2000-10-12 |
2002-04-18 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
JP4317010B2
(ja)
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ，インコーポレイティド |
ＩｇＧ抗体の安定な凍結乾燥医薬製剤
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
US20110313024A1
(en)
|
2004-08-20 |
2011-12-22 |
Leonid Beigelman |
RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
|
ES2366974T3
(es)
|
2006-05-05 |
2011-10-27 |
Isis Pharmaceuticals, Inc. |
Compuestos y procedimientos para modular la expresión de sglt2.
|
|
DK2363481T3
(en)
|
2006-05-05 |
2017-06-26 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gene expression
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
AU2007261536C1
(en)
|
2006-06-16 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
WO2008057457A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
CA2667869A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
CN101636179B
(zh)
|
2006-11-07 |
2012-10-10 |
默沙东公司 |
Pcsk9拮抗剂
|
|
EP2106261A4
(en)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
|
CN101589143A
(zh)
*
|
2006-11-27 |
2009-11-25 |
Isis药物公司 |
用于治疗高胆固醇血症的方法
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EA200901376A1
(ru)
|
2007-04-13 |
2010-12-30 |
Новартис Аг |
Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
WO2009042765A1
(en)
|
2007-09-25 |
2009-04-02 |
The Regents Of The University Of California |
Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders
|
|
KR20100091191A
(ko)
|
2007-10-26 |
2010-08-18 |
쉐링 코포레이션 |
항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
CA2721052C
(en)
|
2008-04-11 |
2023-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
BRPI0917888A2
(pt)
|
2008-09-19 |
2014-02-25 |
Pfizer |
Formulação de anticorpo líquida estável
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
US8748115B2
(en)
|
2008-12-12 |
2014-06-10 |
Merck Sharp & Dohme Corp. |
PCSK9 immunoassay
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
SG174258A1
(en)
|
2009-03-06 |
2011-10-28 |
Genentech Inc |
Antibody formulation
|
|
KR20120050429A
(ko)
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
|
|
EP2442798A4
(en)
|
2009-06-18 |
2013-03-13 |
Wyeth Llc |
LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
|
|
WO2011006000A1
(en)
|
2009-07-08 |
2011-01-13 |
Haiyan Liu |
Berberine derivatives useful for modulating lipid levels and their methods of synthesis
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
WO2011028938A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
WO2011037791A1
(en)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonists of pcsk9
|
|
US20120264146A1
(en)
|
2009-10-02 |
2012-10-18 |
The Regents Of The University Of California |
Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
|
|
US8802827B2
(en)
|
2009-10-30 |
2014-08-12 |
Merck Sharp & Dohme Corp. |
AX1 PCSK9 antagonists
|
|
WO2011053783A2
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax213 and ax132 pcsk9 antagonists and variants
|
|
DK3721904T3
(da)
|
2009-11-20 |
2021-11-15 |
Biocon Ltd |
Formuleringer af t1h-antistof
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
CN105218674A
(zh)
|
2010-03-11 |
2016-01-06 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
DE102010024698A1
(de)
|
2010-06-23 |
2011-12-29 |
Eads Deutschland Gmbh |
Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
|
|
EP3354280B1
(en)
|
2010-10-06 |
2020-07-29 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
|
EP2638073A4
(en)
|
2010-11-09 |
2014-05-07 |
Altimab Therapeutics Inc |
PROTEIN COMPLEXES FOR ANTIGEN BINDING, AND METHODS OF USE
|
|
MX2013007168A
(es)
|
2010-12-22 |
2013-11-04 |
Genentech Inc |
Anticuerpo anti-pcsk9 y metodos de uso.
|
|
WO2012101253A1
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
|
MX2013009258A
(es)
|
2011-02-11 |
2013-10-17 |
Novartis Ag |
Antagonistas de pcsk9.
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
HRP20241450T1
(hr)
|
2011-09-16 |
2025-01-03 |
Regeneron Pharmaceuticals, Inc. |
Postupci za smanjivanje razina lipoproteina(a) putem primjene inhibitora proproteinske konvertaze suptilizin keksin 9 (pcsk9)
|
|
WO2013158984A1
(en)
|
2012-04-19 |
2013-10-24 |
Acetylon Pharmaceuticals, Inc. |
Biomarkers to identify patients that will respond to treatment and treating such patients
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
TWI596115B
(zh)
|
2012-08-13 |
2017-08-21 |
再生元醫藥公司 |
具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
WO2014197752A1
(en)
|
2013-06-07 |
2014-12-11 |
Regeneron Pharmaceuticals, Inc. |
Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9
|
|
JP6846931B2
(ja)
|
2013-10-11 |
2021-03-24 |
サノフィ・バイオテクノロジー |
高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
|
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
KR20160115939A
(ko)
|
2014-02-14 |
2016-10-06 |
리제너론 파아마슈티컬스, 인크. |
중등-용량 스타틴 치료법에 의해 적당하게 조절되지 않는 고콜레스테롤혈증이 있는 환자의 치료 방법
|
|
US20150283236A1
(en)
|
2014-03-17 |
2015-10-08 |
Marie Baccara-Dinet |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
PL3119810T3
(pl)
|
2014-03-17 |
2024-07-15 |
Sanofi Biotechnology |
Sposoby obniżania ryzyka sercowo-naczyniowego
|
|
KR102482375B1
(ko)
|
2014-07-16 |
2022-12-29 |
사노피 바이오테크놀로지 |
고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
|
|
EP3169353B1
(en)
|
2014-07-16 |
2019-12-18 |
Sanofi Biotechnology |
Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
|
|
CN107922507B
(zh)
|
2015-08-18 |
2022-04-05 |
瑞泽恩制药公司 |
抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|